Ari Raphael
6 Weizmann St, 6423906
Tel Aviv, TA 64239, Israel
Tel Aviv, TA 64239, Israel
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
De Novo Actionable Genomic Alterations in High-Grade Pulmonary Neuroendocrine Carcinomas: Therapeutic Implications of Targeted Treatment.
Journal: Medical sciences (Basel, Switzerland)
Published: July 03, 2026
Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non-Small Cell Lung Cancer: Insights From a National Real-World Cohort.
Journal: JCO oncology practice
Published: March 25, 2026
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter Study.
Journal: International journal of radiation oncology, biology, physics
Published: August 13, 2025
Lung Immune Prognostic Index-Based Predictive Score in Advanced Non-Small Cell Lung Cancer with a Programmed Death Ligand-1 Tumor Proportion Score ≥ 50.
Journal: Journal of clinical medicine
Published: March 31, 2025
Real-World Data on Osimertinib-Associated Cardiac Toxicity.
Journal: Journal of clinical medicine
Published: January 27, 2025
Breast cancer is detectable from peripheral blood using machine learning over T cell receptor repertoires.
Journal: NPJ systems biology and applications
Published: December 20, 2024
Body composition measures as a determinant of Alpelisib related toxicity.
Journal: Breast cancer research and treatment
Published: January 15, 2024
High neutrophil-to-lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracycline.
Journal: Clinical cardiology
Published: October 21, 2022
Valvular Heart Disease following Anthracycline Therapy-Is It Time to Look beyond Ejection Fraction?
Journal: Life (Basel, Switzerland)
Published: July 19, 2022
FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).
Journal: Journal of clinical medicine
Published: March 21, 2022
Last Updated: 09/26/2026